Literature DB >> 403235

Mitogen activation of human chronic lymphatic leukemia cells. I. Synthesis and secretion of immunoglobulin.

V C Maino, J T Kurnick, R T Kubo, H M Grey.   

Abstract

The response of CLL (chronic lymphatic leukemia) lymphocytes to PHA, PWM, and Con A with respect to changes in surface markers and synthesis and secretion of immunoglobulin were examined. After PHA stimulation the percentage of cells bearing readily detectable surface immunoglobulin (SmIg) diminished rapidly whereas cells forming rosettes with sheep erythrocytes (E-rosettes) increased from less than 1% to 30 to 50%. The great majority of blast-transformed cells were E-rosette-positive cells with a small population of SmIg-positive blast cells also observed. Ig production in four of seven CLL lymphocyte populations was increased 2.5 to greater than 40-fold after 4 to 6 days of culture in the presence of PHA. In contrast, pokeweed mitogen did not affect Ig synthesis. Furthermore, the Ig secreted into the culture supernatant fluids from seven of eight CLL cases examined consisted almost entirely of free light chain molecules. In contrast, the cell lysates contained a significant proportion of intact Ig molecules. These results indicate that CLL cells can, under certain circumstances, be stimulated to synthesize and secrete increased amounts of Ig, but that there is a basic defect in the biosynthetic mechanism of these cells which result in the secretion of free light chains rather than intact immunoglobulin molecules.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 403235

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Free immunoglobulin light chain synthesis by lymphocytes from patients with hypogammaglobulinaemia.

Authors:  J Gordon; J L Smith
Journal:  Clin Exp Immunol       Date:  1978-11       Impact factor: 4.330

2.  Biosynthesis and characterisation of IgMlambda in a case of chronic lymphocytic leukaemia with intracellular immunoglobulin inclusions.

Authors:  G H Roberts; J Gordon; J L Smith; D Newell; R Pike
Journal:  J Clin Pathol       Date:  1979-03       Impact factor: 3.411

3.  Urine free light chains in SLE: clonal markers of B-cell activity and potential link to in vivo secreted Ig.

Authors:  J E Hopper; J Golbus; C Meyer; G A Ferrer
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

4.  Free immunoglobulin light chain synthesis by neoplastic cells in leukaemic reticuloendotheliosis.

Authors:  J Gordon; J L Smith
Journal:  Clin Exp Immunol       Date:  1978-02       Impact factor: 4.330

5.  Cell surface markers in chronic lymphatic leukaemia.

Authors: 
Journal:  Br Med J       Date:  1979-10-13

6.  Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia.

Authors:  Matthew J Maurer; James R Cerhan; Jerry A Katzmann; Brian K Link; Cristine Allmer; Clive S Zent; Timothy G Call; Kari G Rabe; Curtis A Hanson; Neil E Kay; Susan L Slager; Thomas E Witzig; Tait D Shanafelt
Journal:  Blood       Date:  2011-07-15       Impact factor: 22.113

7.  The roles of leukaemic and residual normal cells in the proliferative response of chronic lymphocytic leukaemic lymphocytes to mitogens.

Authors:  A P Johnstone; R E Millard; L Hudson
Journal:  Clin Exp Immunol       Date:  1982-03       Impact factor: 4.330

8.  Mitogen-stimulated immunoglobulin production by chronic lymphocytic leukaemic lymphocytes.

Authors:  A P Johnstone; J C Jensenius; R E Millard; L Hudson
Journal:  Clin Exp Immunol       Date:  1982-03       Impact factor: 4.330

9.  Induction of amplified synthesis and secretion of IgM by fusion of murine 'b lymphoma with myeloma cells.

Authors:  R Laskov; K J Kim; R Asofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

10.  Chronic lymphocytic leukemia cells lack the 185,000-dalton macromolecular insoluble cold globulin present on normal B lymphocytes.

Authors:  M A Simmonds; G Sobczak; S P Hauptman
Journal:  J Clin Invest       Date:  1981-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.